Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy

被引：0
|
作者：
Casamassima, A.
Guida, M.
Picciariello, M.
Giampaglia, M.
Porcelli, G.
Lamacchia, P.
Quaranta, M.
Lorusso, V.
机构：
[1] Inst Oncol, Dept Expt Oncol, Immunol Lab, Bari, Italy
[2] Inst Oncol, Dept Med Oncol, Bari, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [1] Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy
    Guida, M.
    Casamassima, A.
    Picciariello, M.
    Giampaglia, M.
    Porcelli, G.
    Lamacchia, P.
    Quaranta, M.
    Lorusso, V.
    ANNALS OF ONCOLOGY, 2005, 16 : 79 - 79
  • [2] Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors
    Michele Guida
    Addolorata Casamassima
    Giulia Monticelli
    Michele Quaranta
    Giuseppe Colucci
    Journal of Translational Medicine, 5
  • [3] Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors
    Guida, Michele
    Casamassima, Addolorata
    Monticelli, Giulia
    Quaranta, Michele
    Colucci, Giuseppe
    JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5 (1)
  • [4] CRP: A BIOMARKER OF SURVIVAL IN METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED WITH SUBCUTANEOUS IL-2-BASED IMMUNOTHERAPY
    Guida, M.
    Casamassima, A.
    Picciariello, M.
    Berardino, R.
    Ranieri, C.
    Montenegro, E.
    Quaranta, M.
    Lorusso, V.
    ANNALS OF ONCOLOGY, 2004, 15 : 40 - 40
  • [5] Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
    Michael B. Atkins
    Medical Oncology, 2009, 26 : 18 - 22
  • [6] Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
    Atkins, Michael B.
    MEDICAL ONCOLOGY, 2009, 26 : 18 - 22
  • [7] HISTOLOGIC-CHANGES IN RENAL-CELL CARCINOMA FOLLOWING IL-2-BASED IMMUNOTHERAPY
    MERINO, MJ
    SPENCER, WF
    LINEHAN, M
    ROSENBERG, SA
    LABORATORY INVESTIGATION, 1991, 64 (01) : A49 - A49
  • [8] The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies
    Beebe, Kirk D.
    Eisner, Joel R.
    Guo, John
    Shibata, Yoichiro
    Davison, James M.
    Uronis, Josh
    Farhangfar, Carol
    Farhangfar, Farhang
    Mooney, Jill
    Milburn, Michael V.
    White, Richard L.
    Amin, Asim
    Milla, Marcos E.
    Foureau, David M.
    JOURNAL OF IMMUNOLOGY, 2024, 213 (01): : 29 - 39
  • [9] Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: Evidence for non-renal clearance of cytokines
    Banks, RE
    Forbes, MA
    Hallam, S
    Jenkins, A
    Wadhwa, M
    Dilger, P
    Meager, A
    Thorpe, R
    Bowmer, CJ
    Patel, P
    Johnson, PWM
    Selby, PJ
    BRITISH JOURNAL OF CANCER, 1997, 75 (12) : 1842 - 1848
  • [10] Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines
    RE Banks
    MA Forbes
    S Hallam
    A Jenkins
    M Wadhwa
    P Dilger
    A Meager
    R Thorpe
    CJ Bowmer
    JK Joffe
    P Patel
    PWM Johnson
    PJ Selby
    British Journal of Cancer, 1997, 75 : 1842 - 1848
12345